quinidine has been researched along with midazolam in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.00) | 18.2507 |
| 2000's | 16 (40.00) | 29.6817 |
| 2010's | 18 (45.00) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giacomini, KM; Schaner, ME; Zhang, L | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Dai, R; Liu, Y; She, M; Wu, Z | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Gunaydin, H; Sun, Y; Weiss, MM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL | 1 |
| Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
| Chen, J; Follath, F; Freiburghaus, AU; Ha, HR; Leuenberger, PM | 1 |
| Bayliss, MK; Eddershaw, PJ; Herriott, D; Manchee, GR; Park, GR; Ranshaw, LE; Tarbit, MH | 1 |
| Birkett, DJ; Coville, PF; Miners, JO; Walker, RJ; Wanwimolruk, S; Zhang, H | 1 |
| Bigler, L; Follath, F; Ha, HR; Kozlik, P; Stieger, B | 1 |
| Galetin, A; Hallifax, D; Houston, JB; Ito, K | 1 |
| Bhoopathy, S; Karnes, HT; Unger, SE; Xin, B | 1 |
| Foti, RS; Rock, DA; Wahlstrom, JL; Wienkers, LC | 1 |
| Baba, K; Hamahata, Y; Hayashi, M; Iwanaga, K; Kakemi, M; Miyazaki, M; Shibano, M; Taniguchi, M | 1 |
| Agrawal, V; Choi, JH; Giacomini, KM; Miller, WL | 1 |
| Chen, Y; Subramanian, R; Zhu, X | 1 |
| Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y | 1 |
| Ishigai, M; Kato, M; Mitsui, T; Miyake, T; Nagao, S; Nemoto, T; Ogawa, K; Yamada, H | 1 |
1 review(s) available for quinidine and midazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for quinidine and midazolam
| Article | Year |
|---|---|
Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Topics: Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Hydrocortisone; Hydroxycholesterols; Midazolam; Quinidine; Quinine; Rifampin | 2014 |
38 other study(ies) available for quinidine and midazolam
| Article | Year |
|---|---|
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa).
Topics: Carrier Proteins; Corticosterone; HeLa Cells; Humans; Membrane Proteins; Midazolam; Organic Cation Transporter 1; Permeability; Recombinant Proteins; Structure-Activity Relationship; Tetraethylammonium Compounds; Transfection | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
Topics: Cytochrome P-450 Enzyme Inhibitors; Enzyme Activation; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Molecular Structure; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.
Topics: | 2013 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; Freund's Adjuvant; Humans; Lipopolysaccharides; Male; Mice; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Structure-Activity Relationship | 2021 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
In vitro inhibition of midazolam and quinidine metabolism by flavonoids.
Topics: Anti-Arrhythmia Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Flavonoids; Humans; Kinetics; Midazolam; Mixed Function Oxygenases; Quinidine | 1995 |
The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Topics: Adrenergic beta-Agonists; Albuterol; Biomarkers; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Disulfiram; Humans; Isoenzymes; Ketoconazole; Microsomes, Liver; Midazolam; Molecular Structure; Oxidation-Reduction; Quinidine; Recombinant Proteins; Salmeterol Xinafoate; Sulfaphenazole; Theophylline | 1996 |
Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Topics: Antimalarials; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Isoenzymes; Kinetics; Male; Microsomes, Liver; Midazolam; Middle Aged; Oxidoreductases, N-Demethylating; Quinidine; Quinine | 1997 |
Metabolism of amiodarone (Part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone.
Topics: Amiodarone; Animals; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Chromatography, High Pressure Liquid; Cimetidine; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ketoconazole; Kinetics; Microsomes, Liver; Midazolam; Models, Chemical; Oxidoreductases, N-Demethylating; Protein Isoforms; Quinidine; Rabbits; Rifampin; Time Factors | 2001 |
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
Topics: Algorithms; Anti-Arrhythmia Agents; Area Under Curve; Azoles; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Forecasting; Humans; Hypnotics and Sedatives; In Vitro Techniques; Kinetics; Microsomes; Midazolam; Nifedipine; Quinidine; Substrate Specificity; Testosterone | 2005 |
A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
Topics: Algorithms; Animals; Antitussive Agents; Chlorpromazine; Chromatography, Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Half-Life; Humans; Hypnotics and Sedatives; In Vitro Techniques; Indicators and Reagents; Isoenzymes; Microsomes, Liver; Midazolam; Pharmaceutical Preparations; Primaquine; Quinidine; Rats; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2005 |
Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
Topics: Algorithms; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Felodipine; Microsomes, Liver; Midazolam; Molecular Structure; Nifedipine; Quinidine; Substrate Specificity; Testosterone | 2010 |
Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
Topics: Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Furocoumarins; Humans; Medicine, Kampo; Midazolam; Quinidine | 2010 |
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
Topics: Biocatalysis; Cytochrome P-450 CYP3A; Erythromycin; Genetic Variation; Humans; Kinetics; Midazolam; Mutant Proteins; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Quinidine; Substrate Specificity; Testosterone | 2010 |
Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
Topics: Algorithms; Animals; Biotransformation; Chlorpromazine; Chromatography, High Pressure Liquid; Ethanolamines; Microsomes, Liver; Midazolam; Oxidation-Reduction; Quinidine; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
A useful model capable of predicting the clearance of cytochrome 3A4 (CYP3A4) substrates in humans: validity of CYP3A4 transgenic mice lacking their own Cyp3a enzymes.
Topics: Alprazolam; Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Felodipine; Humans; Male; Mice; Mice, Transgenic; Microsomes, Liver; Midazolam; Nifedipine; Nitrendipine; Quinidine | 2014 |